


Section 1: Identification

| | | |
|-----------------------------------|--|---|
| Common Name/Trade Name | Mometasone Furoate USP | |
| Supplier Information | Letco Medical, LLC 1316 Commerce Drive NW Decatur, AL 35601 1 (800) 239-5288 +1 (734) 843-4693 | IN CASE OF EMERGENCY: Chemtrec 1 (800) 424-9300 (24 hours) |
| Distributor Name | Bella Corp Trading Pty Ltd 6/34 Dominions Road, Ashmore QLD 4214, Australia Telephone: 07 5597 4169 Email: bellacorp@bellacorp.com.au | |
| Product Synonym(s) | N/A | |
| Relevant Use(s) of Product | Manufacture or Compounding of Substances | |

Section 2: Hazards Identification

| | | |
|---|--|---|
| Classification of Substance or Mixture | Reproductive toxicity Category 2. Specific target organ toxicity, repeated exposure Category 1 (endocrine system). | |
| Signal Word | Danger | |
| Hazard Statement(s) | H361 H372 | Suspected of damaging fertility or the unborn child Causes damage to organs through prolonged or repeated exposure |
| Pictogram(s) |  | |
| Precautionary Statement(s) | P201 P202 P264 P270 P280 P308+P313 P405 P501 | Obtain special instructions before use. Do not handle until all safety precautions have been read and understood. Wash hands thoroughly after handling. Do not eat, drink or smoke when using this product. Wear protective gloves/protective clothing/eye protection/face protection. IF exposed or concerned Get medical advice/attention. Store locked up. Dispose of contents/container to an approved waste disposal plant. |
| Hazards Not Otherwise Classified | Not classified. | |
| Ingredient(s) with Unknown Toxicity | No data available | |

Section 3: Composition/Information on Ingredients

| | |
|--|--|
| Chemical Name | Mometasone Furoate. Pregna-1,4-diene-3,20-dione, 9,21-dichloro-17-[(2-furanylcarbonyl)oxy]-11-hydroxy-16-methyl-, (11beta, 16alpha)- |
| Common Name | Mometasone Furoate |
| CAS Number | 83919-23-7 |
| Impurities and/or Stabilizing Additives | No data available |

Section 4: First Aid Measures

| | |
|--|---|
| General Advice | Remove from exposure. Remove contaminated clothing. For treatment advice, seek guidance from an occupational health physician or other licensed healthcare provider familiar with workplace chemical exposures. In the United States, the national poison control center phone number is 1-800-222-1222. If person is not breathing, give artificial respiration. If breathing is difficult, give oxygen if available. Persons developing serious hypersensitivity (anaphylactic) reactions must receive immediate medical attention. |
| If Inhaled | If breathing is difficult, remove to fresh air and keep at rest in a position comfortable for breathing. Call a physician if symptoms develop or persist. |
| In Case of Skin Contact | Rinse skin with water/shower. Get medical attention if irritation develops and persists. |
| In Case of Eye Contact | Rinse with water. Get medical attention if irritation develops and persists. |
| If Swallowed | Rinse mouth. If ingestion of a large amount does occur, call a poison control center immediately. |
| Most Important Symptoms and Effects | Not available. Indication of immediate medical attention and special treatment needed Acute toxicity following overdose is uncommon. Gastrointestinal decontamination is generally not necessary. Treatment should be symptomatic and supportive. [Poisindex 2010] |

Section 5: Fire Fighting Measures

| | |
|---|---|
| Suitable Extinguishing Media | Water spray, dry chemical, carbon dioxide, or foam as appropriate for surrounding fire and materials. |
| Special Hazards Arising From the Substance/Mixture | No unusual fire or explosion hazards noted. |
| Special PPE and/or Precautions for Firefighters | Wear suitable protective equipment. As with all fires, evacuate personnel to a safe area. Firefighters should use self-contained breathing equipment and protective clothing. Specific methods Cool containers exposed to flames with water until well after the fire is out. |

Section 6: Accidental Release Measures

| | |
|--|---|
| Personal Precautions, Protective Equipment and Emergency Procedures | Keep unnecessary personnel away. Do not touch damaged containers or spilled material unless wearing appropriate protective clothing. Avoid inhalation of dust from the spilled material. Ensure adequate ventilation. Wear appropriate personal protective equipment. |
| Methods and Materials Used for Containment | Sweep up or vacuum up spillage and collect in suitable container for disposal. Avoid the generation of dusts during clean-up. For waste disposal, see section 13 of the SDS. Wash spill site. |
| Cleanup Procedures | Sweep up or vacuum up spillage and collect in suitable container for disposal. Avoid the generation of dusts during clean-up. For waste disposal, see section 13 of the SDS. Wash spill site. |

Section 7: Handling and Storage

| | |
|--------------------------------------|---|
| Precautions for Safe Handling | Avoid all contact and inhalation of dust, mists, and/or vapors associated with the material. Clean equipment and work surfaces with suitable detergent or solvent after use. After removing gloves, wash hands and other exposed skin thoroughly. |
| Conditions for Safe Storage | Store in tight container as defined in the USP-NF. This material should be handled and stored per label instructions to ensure product integrity. |

Section 8: Exposure Controls/Personal Protection

| | |
|---|---|
| Components with Workplace Control Parameters | Biological limit values No biological exposure limits noted for the ingredient(s). Exposure guidelines No exposure standards allocated. |
| Appropriate Engineering Controls | Airborne exposure should be controlled primarily by engineering controls such as general dilution ventilation, local exhaust ventilation, or process enclosure. Local exhaust ventilation is generally preferred to general exhaust because it can control the contaminant at its source, preventing dispersion into the work area. An industrial hygiene survey involving air monitoring may be used to determine the effectiveness of engineering controls. Effectiveness of engineering controls intended for use with highly potent materials should be assessed by use of nontoxic surrogate materials. Avoid any open handling of this material, particularly for grinding, crushing, weighing, or other dust-generating or aerosol-generating procedures. Use a laboratory fume hood, vented enclosure, glovebox, or other effective containment. Handle in accordance with good industrial hygiene and safety practice. |
| PPE - Eye/Face Protection | Safety glasses with side shields are recommended. Face shields or goggles may be required if splash potential exists or if corrosive materials are present. Approved eye protection (e.g., bearing the ANSI Z 87 or CSA stamp) is preferred. Maintain eyewash facilities in the work area. |
| PPE - Skin Protection | Chemically compatible gloves. For handling solutions, ensure that the glove material is protective against the solvent being used. Use handling practices that minimize direct hand contact. Employees who are sensitive to natural rubber (latex) should use nitrile or other synthetic nonlatex gloves. Use of powdered latex gloves should be avoided due to the risk of latex allergy. This material is extremely potent. To reduce the risk of contamination of skin and surfaces, wear two pairs of gloves. Remove the outer gloves after handling and cleanup of the material, and remove the inner gloves only after removing other personal protective equipment. |
| PPE - Body Protection | For handling of laboratory scale quantities, a cloth lab coat is recommended. Where significant quantities are handled, work clothing may be necessary to prevent take-home contamination. |
| PPE - Respiratory Protection | Where respirators are deemed necessary to reduce or control occupational exposures, use NIOSH-approved respiratory protection and have an effective respirator program in place (applicable U.S. regulation OSHA 29 CFR 1910.134). |

Section 9: Physical and Chemical Properties

| | |
|---|--|
| Appearance | White to off-white clumpy powder. |
| Upper/Lower Flammability or Explosive Limits | Not available |
| Odor | Not available |
| Vapor Pressure | Not available |
| Odor Threshold | Not available |
| Vapor Density | Not available |
| pH | Not available |
| Relative Density | Not available |
| Melting Point/Freezing Point | 419 - 442.4 °F (215 - 228 °C) |
| Solubility | Solubility in water Insoluble. Solubility (other) Very soluble in ethanol; soluble in acetone, in dichloromethane, in dioxane, and in methanol; slightly soluble in octanol. |
| Initial Boiling Point and Boiling Range | Not available. |
| Flash Point | Not available. |
| Evaporation Rate | Not available. |
| Flammability (Solid, Gas) | Not applicable. |
| Partition Coefficient | 4.115 |
| Auto-Ignition Temperature | Not available. |
| Decomposition Temperature | Not available. |
| Viscosity | Not available. |

Section 10: Stability and Reactivity

| | |
|---|---|
| Reactivity | No reactivity hazards known. |
| Chemical Stability | Stable at normal conditions. |
| Possibility of Hazardous Reactions | No dangerous reaction known under conditions of normal use. |
| Conditions to Avoid | None known. |
| Incompatible Materials | Strong oxidizers. |
| Hazardous Decomposition Products | Cl-. Irritating and/or toxic fumes or gases. Emits toxic fumes under fire conditions. |

Section 11: Toxicological Information

| | |
|---|---|
| Acute Toxicity - LD50 Oral | LD50 Rat Oral > 2000 mg/kg |
| Acute Toxicity - Inhalation | Due to lack of data the classification is not possible. |
| Acute Toxicity - Dermal | Based on available data, the classification criteria are not met. |
| Acute Toxicity - Eye | Based on available data, the classification criteria are not met. |
| Skin Corrosion/Irritation | Based on available data, the classification criteria are not met. |
| Serious Eye Damage/Irritation | Based on available data, the classification criteria are not met. |
| Respiratory or Skin Sensitization | Due to lack of data the classification is not possible. |
| Germ Cell Mutagenicity | Based on available data, the classification criteria are not met. Mutagenicity Ames test Result: Negative In vitro chromosomal aberration assay in Chinese hamster lung cells Result: Negative In vitro chromosomal aberration assay in Chinese hamster ovary cells Result: Positive In vivo mouse micronucleus assay Result: Negative In vivo unscheduled DNA synthesis assay in rat hepatocytes Result: Negative Mouse lymphoma assay Result: Negative Mouse male germ-cell chromosomal aberration assay Result: Negative Rat bone marrow chromosomal aberration assay Result: Negative |
| Carcinogenicity IARC | Based on available data, the classification criteria are not met. This product is not considered to be a carcinogen by IARC, ACGIH, NTP, or OSHA. |
| Carcinogenicity ACGIH | Based on available data, the classification criteria are not met. This product is not considered to be a carcinogen by IARC, ACGIH, NTP, or OSHA. |
| Carcinogenicity NTP | Based on available data, the classification criteria are not met. This product is not considered to be a carcinogen by IARC, ACGIH, NTP, or OSHA. |
| Carcinogenicity OSHA | Based on available data, the classification criteria are not met. This product is not considered to be a carcinogen by IARC, ACGIH, NTP, or OSHA. |
| Reproductive Toxicity | Suspected of damaging fertility or the unborn child. Most studies have concluded that therapeutic use of corticosteroids by pregnant women does not cause adverse effects on the fetus. A small increase in the incidence of cleft palate was seen in some human studies. Infants born to mothers who received substantial doses of corticosteroids during pregnancy should be observed for signs of hypoadrenalism. Corticosteroids have been shown to cause birth defects in laboratory animals when administered systemically at low doses, and some caused birth defects when administered topically. |
| Specific Target Organ Toxicity - Single Exposure | Based on available data, the classification criteria are not met. |
| Specific Target Organ Toxicity - Repeated Exposure | Causes damage to organs (endocrine system) through prolonged or repeated exposure. |
| Aspiration Hazard | Based on available data, the classification criteria are not met. |

Section 12: Ecological Information

| | |
|--------------------------------------|--|
| Toxicity | There are no data on the ecotoxicity of this product. |
| Persistence and Degradability | No data is available on the degradability of this product. |
| Bio-accumulative Potential | Not available. |
| Mobility in Soil | Not available. |
| Other Adverse Effects | Not available. |

Section 13: Disposal Considerations

| | |
|--|---|
| Waste Treatment Methods Product | This product, in its present state, when discarded or disposed of, is not a hazardous waste according to Federal regulations (40 CFR 261.4 (b)(4)). Under RCRA, it is the responsibility of the user of the product to determine, at the time of disposal, whether the product meets RCRA criteria for hazardous waste. Dispose in accordance with all applicable regulations. |
| Waste Treatment Methods Packaging | Empty containers or liners may retain some product residues. This material and its container must be disposed of in a safe manner (see: Disposal instructions). Contaminated packaging Empty containers should be taken to an approved waste handling site for recycling or disposal. Since emptied containers may retain product residue, follow label warnings even after container is emptied. |
| Special Precautions Landfill or Incinerations | No data available |
| Other Information | No data available |

Section 14: Transport Information

| | |
|-----------------------------------|----------------------|
| UN Number | Not dangerous goods. |
| UN Proper Shipping Name | N/A |
| Transport Hazard Class(es) | N/A |
| Packaging Group | N/A |
| Environmental Hazards | No data available |

Section 15: Regulatory Information

US federal regulations CERCLA/SARA Hazardous Substances - Not applicable. One or more components are not listed on TSCA. Superfund Amendments and Reauthorization Act of 1986 (SARA) Hazard categories Immediate Hazard - No Delayed Hazard - No Fire Hazard - No Pressure Hazard - No Reactivity Hazard - No SARA 302 Extremely hazardous substance No SARA 311/312 Hazardous chemical No Other federal regulations Safe Drinking Water Act (SDWA) Not regulated. Food and Drug Administration (FDA) Not regulated. US state regulations California Safe Drinking Water and Toxic Enforcement Act of 1986 (Proposition 65): This material is not known to contain any chemicals currently listed as carcinogens or reproductive toxins. International Inventories Country(s) or region Inventory name On inventory (yes/no)* Australia Australian Inventory of Chemical Substances (AICS) No Canada Domestic Substances List (DSL) No Canada Non-Domestic Substances List (NDSL) No China Inventory of Existing Chemical Substances in China (IECSC) No Europe European Inventory of Existing Commercial Chemical No Substances (EINECS) Europe European List of Notified Chemical Substances (ELINCS) No Japan Inventory of Existing and New Chemical Substances (ENCS) No Korea Existing Chemicals List (ECL) No New Zealand New Zealand Inventory No Philippines Philippine Inventory of Chemicals and Chemical Substances No (PICCS) United States & Puerto Rico Toxic Substances Control Act (TSCA) Inventory No *A "Yes" indicates that all components of this product comply with the inventory requirements administered by the governing country(s)

Section 16: Other Information

| | |
|-------------------------------|---|
| Additional Information | <p>Information on likely routes of exposure. Ingestion. Based on available data, the classification criteria are not met. Inhalation. Due to lack of data the classification is not possible. Skin contact. Based on available data, the classification criteria are not met. Eye contact. Based on available data, the classification criteria are not met. Symptoms related to the physical, chemical, and toxicological characteristics. Mineralocorticoid effects: Swelling. Confusion. Lightheadedness. Nausea. Vomiting. Numbness. Tremors. Glucocorticoid effects: Bone fractures. Back pain. Joint pain or stiffness. Weakness. Increased appetite. Infection. Delayed wound healing. Thinning skin. Bruising. Purple lines on skin. Increased hair growth. Acne. Redistribution of body fat. Menstrual irregularities. Impotence. Headache. Increased sweating. Eye pain. Change in vision. Mental or behavioral changes. Withdrawal effects: Fever. Muscle pain. Joint pain. Malaise. Delayed and immediate effects of exposure Corticosteroids: Fluid and electrolyte imbalance. Cushing's syndrome. Adrenal suppression. Immune system depression. Withdrawal. Cross sensitivity Persons sensitive to one corticosteroid may be sensitive to this material also. Medical conditions aggravated by exposure Corticosteroids: Heart disease. High blood pressure. Diabetes. Epilepsy. Glaucoma. Hypothyroidism. Osteoporosis. Peptic ulcer. Systemic fungal infection. Mental disorders. Impaired liver or kidney function. Acute toxicity. Based on available data, the classification criteria are not met.</p> |
| Prepared By | Lisa Russell |
| Revision Date | 01/03/2019 15:56 |

Disclaimer

Letco Medical, LLC believes that the above information is correct but does not purport to be all inclusive and shall be used only as a guide. The information in this document is based on the present state of our knowledge and is applicable to the product with regard to appropriate safety precautions. If the product is used as a component in another product, this information may not be applicable. NO WARRANTY OF FITNESS FOR ANY PARTICULAR PURPOSE, WARRANTY OF MERCHANTABILITY OR ANY OTHER WARRANTY, EXPRESSED OR IMPLIED, IS MADE CONCERNING THE INFORMATION PROVIDED ABOVE. Letco Medical shall not be held liable for any loss or damage resulting from handling, storage, use or from contact with the above product.